Gourt > Health > Pharmacy > Drugs and Medications > F > Fulvestrant
Fulvestrant, also known as ICI 182,780, is a drug treatment of hormone receptor positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.S. Kansra, S. Yamagata, L. Sneade, L. Foster & N. Ben-Jonathan, 2005. "Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release." Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36. It is administered as a once-monthly injection.
Fulvestrant is marketed by AstraZeneca with the brand name Faslodex.
References
fulvestrant w/ or w/o dasatinib in men & postmenopausal women who have hormone receptor-positive advanced breast cancer http://bit.ly/58bMky
_clinical_trial (Clinical Trials) Mon, 21 Dec 2009 07:38:36 -0000
fulvestrant w/ or w/o dasatinib in men & postmenopausal women who have hormone receptor-positive advanced breast cancer http://bit.ly/58bMky
fulvestrant w/ or w/o dasatinib in men & postmenopausal women who have hormone receptor-positive advanced breast cancer http://bit.ly/58bMky
ustrials (US Trials) Mon, 21 Dec 2009 07:10:35 -0000
fulvestrant w/ or w/o dasatinib in men & postmenopausal women who have hormone receptor-positive advanced breast cancer http://bit.ly/58bMky
Fulvestrant RSS feed
500
Faslodex - AstraZeneca - Provides medication information for patients and U.S. healthcare professionals
Faslodex Consumer Information - FDA - Patient FAQ in html format with a link to approved labeling in pdf format.
Fulvestrant - FamilyDoctor.org - Information for patients in English or Spanish.
